Smart Pharmaceuticals: Witty Health’s smart pharmaceuticals are digital applications customized to specific classes of drugs such as CDK 4/6 and Checkpoint inhibitors. We have currently two products under development- SmartCDK and SmartI-O.
The SmartCDK is a digital therapeutic under clinical development to treat patients with metastatic breast cancer. It is a custom app to monitor toxicity and side effects during treatments with CDK 4/6 inhibitors such as Palbociclib, Ribociclib and Abemaciclib with either Fulvestrant or an Aromatase inhibitor.
We believe, when our SmartCDK is used in combination with a CDK 4/6 inhibitor, it will improve patient’s Quality of Life and reduce healthcare costs. Once the clinical data is available, a new drug application would be filed with the FDA for approval as a prescription-only digital therapeutic.
The SmartI-O is a custom built digital therapeutic for checkpoint inhibitors. It can monitor unexpected and rate side effects associated with any of the five checkpoint inhibitors and their combinations.